GlassScriptPhysician profile
Vladimar A Titov
NPI 1982666905
$5,949.37
in general payments reported to CMS, 2019-2025
62 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $401 · 2021: $46.15 · 2022: $554 · 2023: $1,489 · 2024: $1,208 · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,291.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $611.89 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $434.27 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $427.04 | 2021-2025 | Darzalex, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals LP | $371.68 | 2019-2025 | Breztri, Calquence, Tagrisso |
| Novo Nordisk INC | $341.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $322.55 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $282.49 | 2023-2025 | |
| Pfizer INC. | $238.69 | 2019-2025 | |
| Astellas Pharma US INC | $168.83 | 2024-2025 | Veozah |
| Abbvie INC. | $159.54 | 2019-2025 | Vraylar |
| Dexcom, INC. | $156.95 | 2022-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $153.76 | 2019-2020 | |
| Glaxosmithkline, LLC. | $145.92 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $128.69 | 2019-2025 | |
| Amgen INC. | $122.10 | 2019-2024 | Otezla, Repatha, Lumakras |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $119.02 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $111.84 | 2023-2024 | Libtayo |
| Tandem Diabetes Care, INC. | $96.87 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $90.37 | 2023-2025 | |
| Abbott Laboratories | $86.00 | 2022-2025 | Freestyle Libre 3 |
| Viiv Healthcare Company | $65.14 | 2024-2025 | Apretude |
| Madrigal Pharmaceuticals | $63.03 | 2025 | Rezdiffra |
| Mannkind Corporation | $60.80 | 2023-2025 | Afrezza |
| Adc Therapeutics America, INC. | $56.88 | 2025 | |
| Kyowa Kirin, INC. | $56.12 | 2024 | Crysvita |
| Xeris Pharmaceuticals, INC. | $53.45 | 2025 | Recorlev |
| Springworks Therapeutics, INC. | $53.00 | 2025 | Ogsiveo |
| Takeda Pharmaceuticals U.S.A., INC. | $50.96 | 2023 | |
| Tactile Systems Technology INC | $49.99 | 2023 | Flexitouch Plus, Entre Plus |
| Pharmacosmos Therapeutics INC. | $48.76 | 2023-2024 | Monoferric |
| Organogenesis INC. | $42.11 | 2022 | |
| Azurity Pharmaceuticals, INC. | $41.41 | 2024-2025 | Vivimusta, Danziten |
| Sumitomo Pharma America, INC. | $38.08 | 2023 | Gemtesa |
| Genentech USA, INC. | $34.68 | 2023 | Avastin, Gavreto, Alecensa |
| Foundation Medicine, INC. | $32.67 | 2023 | |
| Corcept Therapeutics | $32.14 | 2025 | Korlym |
| Agios Pharmaceuticals, INC. | $31.92 | 2025 | Pyrukynd |
| Linus Health, INC. | $31.43 | 2024 | Core Cognitive Evaluation |
| Boston Scientific Corporation | $31.35 | 2020 | |
| Alexion Pharmaceuticals, INC. | $30.44 | 2023 | Strensiq |
| Teva Pharmaceuticals USA, INC. | $29.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.21 | 2025 | |
| Seagen INC. | $27.90 | 2023 | Tukysa |
| Edwards Lifesciences Corporation | $24.87 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sun Pharmaceutical Industries INC. | $24.67 | 2019 | |
| Amarin Pharma, INC. | $24.17 | 2020 | |
| Tempus Ai, INC | $24.12 | 2025 | Xt Cdx |
| Aurinia Pharma U.S., INC. | $24.02 | 2022 | |
| Davol INC. | $22.60 | 2024 | Phasix Mesh |
| Pharmacyclics LLC, An Abbvie Company | $22.13 | 2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $21.94 | 2025 | Eliquis |
| Exact Sciences Corporation | $21.32 | 2023 | Cologuard Collection Kit |
| Progenics Pharmaceuticals, INC. | $21.03 | 2024 | |
| Beigene USA, INC. | $20.37 | 2024 | Brukinsa |
| Hikma Pharmaceuticals USA | $20.36 | 2019 | |
| Sequel Med Tech, LLC | $19.48 | 2025 | Twiist |
| Irhythm Technologies, INC. | $18.40 | 2020 | |
| Cequr Corporation | $18.27 | 2023 | Cequr Simplicity |
| Horizon Therapeutics Plc | $17.15 | 2023 | Krystexxa |
| Stryker Corporation | $16.51 | 2025 | Molli |
| Almatica Pharma LLC | $14.54 | 2025 | Loreev Xr, Teriparatide |
| Collegium Pharmaceutical, INC. | $14.23 | 2023 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladimar Titov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.